Davood Khoda-Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared a post on LinkedIn about a recent paper by Lakshya Seth et al. published in JAMA Network:
“Trastuzumab_emtansine had the lowest incidence of LVEF_decrease in ERBB2-Positive Advanced Breast Cancer, and trastuzumab deruxtecan, trastuzumab plus chemotherapy, and trastuzumab plus pertuzumab plus chemotherapy had similar incidences of LVEF decrease.”
Title: Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast CancerA Systematic Review and Meta-Analysis
Authors: Lakshya Seth, Aditya Bhave, Sai Kollapaneni, Viraj Shah, Tarek Nahle, Anne Blaes, Susan Dent, Sara A. Hurvitz, Avirup Guha
Read the Full Article in JAMA Network.
More posts featuring Davood Khoda-Amorzideh on OncoDaily.